Phase 2 MSI Clinical Trials
16 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–16 of 16 trials
Recruiting
Phase 1Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
Advanced Solid Tumors CancerMSI-H Cancer
Nimbus Wadjet, Inc.134 enrolled22 locationsNCT06898450
Recruiting
Phase 2
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Phase 2
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Esophageal CancerCervical CancerHepatocellular Carcinoma+9 more
Diwakar Davar880 enrolled1 locationNCT07223424
Recruiting
Phase 1Phase 2
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Colorectal, CancerHepatocellular CarcinomaMelanoma+15 more
7 Hills Pharma, LLC126 enrolled5 locationsNCT06362369
Recruiting
Phase 1Phase 2
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Endometrial CancerAdvanced Solid TumorsMSI-H or dMMR Advanced Solid Tumors+4 more
Eikon Therapeutics160 enrolled10 locationsNCT07262619
Recruiting
Phase 2
Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer
Locally Advanced Rectal CarcinomapMMRMSS+1 more
Zhejiang University50 enrolled1 locationNCT05731726
Recruiting
Phase 2
Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Colorectal, CancerNeoadjuvant TherapyMismatch Repair-deficient (dMMR)+1 more
Sun Yat-sen University270 enrolled1 locationNCT03926338
Recruiting
Phase 2
Zimberelimab Anti-PD1 +/- Domvanalimab in Resectable Mmrd Gastric Cancer
Locally Advanced Gastric AdenocarcinomaMSI-H/dMMR Gastric CancerMSI-H/dMMR Gastroesophageal-junction Cancer
Royal Marsden NHS Foundation Trust50 enrolled9 locationsNCT06250036
Recruiting
Phase 1Phase 2
A Beta-only IL-2 ImmunoTherapY Study
Triple-Negative Breast CancerEsophageal CancerGastric Cancer+34 more
Medicenna Therapeutics, Inc.115 enrolled27 locationsNCT05086692
Recruiting
Phase 2
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Colo-rectal CancerMSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers
Fudan University40 enrolled1 locationNCT07003022
Recruiting
Phase 2
Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors
MelanomaHead and Neck NeoplasmsMSI-H Cancer
University Medical Center Groningen97 enrolled1 locationNCT05483400
Recruiting
Phase 1Phase 2
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University28 enrolled1 locationNCT05426005
Recruiting
Phase 1Phase 2
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Triple-Negative Breast CancerMelanomaCancer+6 more
Simcha IL-18, Inc.316 enrolled6 locationsNCT04787042
Recruiting
Phase 2
Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
Gastric CancerColon CancerMSI-H+1 more
Peking University38 enrolled1 locationNCT06580574
Recruiting
Phase 1Phase 2
Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
Rectal CancerRadiotherapyAnti-PD-1 Antibody+2 more
West China Hospital20 enrolled1 locationNCT04636008
Recruiting
Phase 2
A Clinical Study to Evaluate HLX10 Monotherapy for the Treatment of MSI-H or dMMR Solid Tumors That Failed to Respond to Standard Therapy
MSI-H Solid Malignant Tumor
Shanghai Henlius Biotech108 enrolled33 locationsNCT03941574